Goldman Sachs
IDXG

Goldman Sachs’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Goldman Sachs’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-205
Closed -$3K – 7198
2016
Q3 		$3K Buy
205
+41
+25% +$1.13K ﹤0.01% 6956
2016
Q2 		$5K Sell
164
-15
-8% -$565 ﹤0.01% 6931
2016
Q1 		$5K Buy
+179
New +$4.79K ﹤0.01% 6981
2013
Q4 		– Sell
-153
Closed -$74K – 6873
2013
Q3 		$74K Sell
153
-8
-5% -$3.83K ﹤0.01% 6233
2013
Q2 		$76K Buy
+161
New +$73K ﹤0.01% 5950

Other funds holding IDXG

BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Virtu KCG Holdings
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Ancora Advisors
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Glenmede Trust
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Goldman Sachs's IDXG Position: Q4 2016 in Review

Goldman Sachs sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2016, closing a stake of 205 shares — an estimated $3K sold.

Goldman Sachs first reported a position in IDXG in Q2 2013 and held it in 5 quarters. The position peaked at $76K in Q2 2013. 14 funds tracked by Wall St. Rank hold IDXG as of Q4 2016.

  • Goldman Sachs reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Goldman Sachs sold 205 Interpace Biosciences, Inc. Common Stock shares in Q4 2016, an estimated $3K.
  • Goldman Sachs first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 5 quarters.
  • Goldman Sachs's Interpace Biosciences, Inc. Common Stock position peaked at $76K in Q2 2013.
  • 14 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.